Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC Summary Adding lurbinectedin to maintenance therapy significantly improved outcomes for patients with extensive-stage small cell lung cancer (ES-SCLC) after first-line chemotherapy, according to a recent study. Read More